Clinical Trial Update: ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for ILT-101 in active moderate-to-severe systemic lupus erythematosus has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• ILT-101

Snippet

Sponsor: Iltoo Pharma | Conditions: Systemic Lupus Erythematosus | Phase 2 | Status: COMPLETED